Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (RAVEN)

University Hospital, Clermont-Ferrand

Status

Enrolling

Conditions

Progressive Chronic Lymphocytic Leukemia

CLL

Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Relapsed Chronic Lymphocytic Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT05246345

2021-A00362-39 (Other Identifier)

RNI 2021 GUIEZE

Details and patient eligibility

About

The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.

Full description

The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age greater than or equal to 18 years old;
chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
refractory and/or relapsed disease during or after venetoclax treatment;
tumor samples available.
Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
Patients must be able to express their opposition to be enrolled in this study, if need be.
Patients must be affiliated at the French Social Security system

Exclusion criteria

Patients of their legal guardians refusing to participate